Evidence map›Paper›PMID 27995113›Full record

ArticleProstate international2016

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study.

Shuya Kandori, Takayuki Yoshino, Masakazu Tsutsumi, Atsushi Yamauchi, Mikinobu Ohtani, Yoshiharu Fukuhara, Naoto Miyanaga, Jun Miyazaki, Hiroyuki Nishiyama, Toru Shimazui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shuya KandoriDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Takayuki YoshinoDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Masakazu TsutsumiDepartment of Urology, Hitachi General Hospital, Hitachi, Japan.
Atsushi YamauchiDepartment of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Mikinobu OhtaniDepartment of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Yoshiharu FukuharaDepartment of Urology, Mito Saiseikai General Hospital, Mito, Japan.
Naoto MiyanagaDepartment of Urology, Mito Saiseikai General Hospital, Mito, Japan.
Jun MiyazakiDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Toru ShimazuiDepartment of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan; Department of Urology, Ibaraki Clinical Education and Training Center, Faculty of Medicine, University of Tsukuba, Japan.
University of Tsukuba · JPIbaraki Prefectural Central Hospital · JPMito Saiseikai General Hospital · JPHitachi General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe retrospectively analyzed castration-resistant prostate cancer (CRPC) patients treated with secondary hormonal therapies (SHTs) prior to docetaxel therapy.

methodsThe cases of 73 CRPC patients who underwent docetaxel therapy in 2005-2011 at four hospitals in Ibaraki, Japan were analyzed. We determined the cause-specific survival (CSS) from the start of docetaxel therapy and the time point of CRPC diagnosis, and we compared the CSS achieved with/without prior classical SHTs, which were defined as low-dose steroid and estramustine phosphate.

resultsOf the 73 enrolled patients, 26 underwent docetaxel therapy (DOC group), and 47 underwent SHTs (SHTs-DOC group) as the initial treatment for CRPC. In the docetaxel therapy, the rate of prostate-specific antigen responses were higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%,

conclusionThe induction of SHTs prior to docetaxel therapy is an acceptable treatment option with some survival benefits for CRPC patients without pain and visceral metastases.

Indexed as

Castration-resistant prostate cancerCause-specific survivalDocetaxelSecondary hormonal therapies

Identifiers

PMID27995113
PMCPMC5153431
OpenAlexW2521384785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.